Humana Inc. (NYSE:HUM) Shares Sold by Mackenzie Financial Corp

Mackenzie Financial Corp cut its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 37.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,995 shares of the insurance provider's stock after selling 13,743 shares during the period. Mackenzie Financial Corp's holdings in Humana were worth $5,834,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Forum Financial Management LP increased its stake in Humana by 62.0% during the fourth quarter. Forum Financial Management LP now owns 1,916 shares of the insurance provider's stock worth $486,000 after purchasing an additional 733 shares during the period. Toronto Dominion Bank increased its stake in Humana by 7.4% during the fourth quarter. Toronto Dominion Bank now owns 64,447 shares of the insurance provider's stock worth $16,351,000 after purchasing an additional 4,455 shares during the period. GF Fund Management CO. LTD. purchased a new stake in Humana during the fourth quarter worth about $763,000. Sunbelt Securities Inc. increased its stake in shares of Humana by 49.3% during the fourth quarter. Sunbelt Securities Inc. now owns 609 shares of the insurance provider's stock worth $155,000 after buying an additional 201 shares during the period. Finally, GTS Securities LLC increased its stake in shares of Humana by 104.5% during the fourth quarter. GTS Securities LLC now owns 1,256 shares of the insurance provider's stock worth $319,000 after buying an additional 29,057 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Price Performance

Humana stock traded up $2.83 during midday trading on Friday, reaching $232.91. 2,524,287 shares of the company were exchanged, compared to its average volume of 1,780,835. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The company has a market capitalization of $28.11 billion, a price-to-earnings ratio of 23.41, a P/E/G ratio of 2.05 and a beta of 0.49. The firm's 50-day simple moving average is $257.11 and its 200-day simple moving average is $266.80. Humana Inc. has a 1 year low of $212.45 and a 1 year high of $406.46.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, beating the consensus estimate of $10.07 by $1.51. The company had revenue of $32.11 billion during the quarter, compared to analysts' expectations of $32 billion. Humana had a return on equity of 11.70% and a net margin of 1.02%. The firm's revenue was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $7.23 EPS. On average, analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.52%. The ex-dividend date of this dividend is Friday, June 27th. Humana's dividend payout ratio (DPR) is 25.04%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on HUM. Robert W. Baird upped their target price on shares of Humana from $270.00 to $300.00 and gave the stock a "neutral" rating in a research note on Tuesday, April 15th. Oppenheimer upped their price target on Humana from $300.00 to $310.00 and gave the company an "outperform" rating in a report on Thursday, May 1st. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $283.00 price target on shares of Humana in a report on Wednesday, February 12th. Cantor Fitzgerald reissued a "neutral" rating and issued a $290.00 price objective on shares of Humana in a report on Thursday, May 1st. Finally, JPMorgan Chase & Co. decreased their price objective on Humana from $257.00 to $256.00 and set a "neutral" rating for the company in a report on Tuesday, February 18th. Sixteen investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $286.81.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.